DKK409.9m market cap
DKK2.05 last close
BioPorto is a diagnostic company focused on the development and marketing antibodies and other products for research and diagnostics. This includes products marketed for research use and The NGAL Test for the prediction of kidney failure.
Investment summary
BioPorto’s lead strategic goal is development of a test for acute kidney injury (AKI) using the biomarker NGAL. The company is gathering more data for its pediatric urine NGAL 510(k) and expects to submit in Q220. For adults using plasma NGAL, the pivotal clinical trial is being completed with the 510(k) to be submitted to the FDA after the submission for pediatric. The NGAL test is commercially available for research purposes in the US and has been CE marked in Europe. BioPorto also sells a series of other antibodies, ELISA kits and related biologics.
Y/E Dec |
Revenue (DKKm) |
EBITDA (DKKm) |
PBT (DKKm) |
EPS (ore) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2018A | 26.0 | (42.1) | (42.5) | (0.24) | N/A | N/A |
| 2019A | 26.6 | (68.3) | (71.1) | (0.39) | N/A | N/A |
| 2020E | 35.5 | (63.2) | (63.3) | (0.33) | N/A | N/A |
| 2021E | 135.2 | 17.3 | 17.2 | 0.09 | 2277.8 | N/A |
Industry outlook
The current standard of care for detecting AKI is serum creatinine, which can take 24 hours or more to detect AKI and can only do so after significant kidney damage. NGAL promises to provide a quicker and more reliable test, allowing early intervention to preserve kidney function.
Last updated on 27/03/2020
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net debt (DKKm) | 37.8 |
| Forecast gearing ratio (%) | 112 |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Thomas Magnussen | Chairman |
| Peter Mørch Eriksen | CEO |
| Ole Larsen | CFO |
| Jan Kuhlmann Andersen | COO |
You may also be interested in…
- 4SC
- Acacia Pharma
- Acarix
- ADL Bionatur Solutions
- Adocia
- ASIT biotech
- Basilea Pharmaceutica
- Bonesupport
- Brighter
- Cantargia
- Carmat
- Celyad
- Deinove
- Formycon
- Herantis Pharma
- Hybrigenics
- Immunicum
- Immunovia
- Kiadis Pharma
- Laboratorios Farmacéuticos ROVI
- MagForce
- Medigene
- MOLOGEN
- Nanobiotix
- NeuroVive Pharmaceutical
- Newron Pharmaceuticals
- Nuevolution
- Oncology Venture
- Onxeo
- Orexo
- Oryzon Genomics
- OSE Immunotherapeutics
- Paion
- Photocure
- Pixium Vision
- Probiodrug
- Quantum Genomics
- RhoVac
- Ryvu Therapeutics
- Targovax
- Transgene
- TxCell
- Xbrane Biopharma